Ken Griffin Next Cure, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$1.03 - $1.45 $1,339 - $1,885	-1,300 Reduced 86.67%	200 $0
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $70,413 - $89,094	-47,900 Reduced 96.96%	1,500 $2,000
Q1 2023 May 15, 2023	SELL	$1.46 - $1.83 $17,520 - $21,960	-12,000 Reduced 19.54%	49,400 $73,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $2.49 $46,080 - $95,616	38,400 Added 166.96%	61,400 $86,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $5.19 $66,825 - $116,775	-22,500 Reduced 49.45%	23,000 $63,000

15.9M

10.5K

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $46.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.